mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma Meeting Abstract


Authors: Sangro, B.; Kudo, M.; Erinjeri, J.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; Chuken, Y. A. L.; Yoon, J. H.; Tak, W. Y.; Suttichaimongkol, T.; Bouattour, M.; Lin, S. M.; Żotkiewicz, M.; Ali, S.; Cohen, G.; Lencioni, R.
Abstract Title: mRECIST outcomes in EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
Meeting Title: European Association for the Study of the Liver (EASL) Congress 2024
Journal Title: Journal of Hepatology
Volume: 80
Issue: Suppl. 1
Meeting Dates: 2024 Jun 5-8
Meeting Location: Milan, Italy
ISSN: 0168-8278
Publisher: Elsevier Science, Inc.  
Date Published: 2024-06-01
Start Page: S3
Language: English
ACCESSION: WOS:001278309400006
PROVIDER: wos
DOI: 10.1016/S0168-8278(24)00428-8
Notes: Meeting Abstract: GS-005 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph Patrick Erinjeri
    203 Erinjeri